Anti-emicizumab antibodies and their relevance in clinical practice
The present findings confirm that the development of anti-emicizumab antibodies is a rare event, particularly those with neutralizing activity. Routine monitoring should be reserved only for patients with clinical manifestations of bleeding when therapy failure is suspected.
Authors
- Lucia Schiavone (ORCID: https://orcid.org/0000-0002-8112-5512)
- Cristina Novembrino (ORCID: https://orcid.org/0000-0003-1450-9935)
- Sara Arcudi (ORCID: https://orcid.org/0000-0001-5743-9098)
- Flora Peyvandi (ORCID: https://orcid.org/0000-0001-7423-9864)
- Carla Valsecchi (ORCID: https://orcid.org/0000-0003-3414-0119)
- Adriana Torri
Institutions
- University of Milan (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
Publication Details
- Journal
- Research and Practice in Thrombosis and Haemostasis
- Published
- 2025-12-06
- DOI
- https://doi.org/10.1016/j.rpth.2025.103282
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00